Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990342 | 0.70 | CHRM2 (0.36) | CHRM2CHRM3MAPK1ALDH1A1ATM | |
| SCHEMBL1779347 | 0.66 | USP2 (0.51) | USP2SMN1; SMN2CYP2C9GPR119 | |
| SCHEMBL18389853 | 0.66 | USP2 (0.40) | CHRM2CHRM3CHRM1MAPK1USP2 | |
| SCHEMBL18195616 | 0.65 | SCN1A (0.39) | USP2SMN1; SMN2 | |
| SCHEMBL3658980 | 0.65 | BUB1 (0.38) | CHRM2CHRM3CHRM1USP2SMN1; SMN2 | |
| SCHEMBL20456344 | 0.65 | CHRM2 (0.37) | CHRM2CHRM3CHRM1USP2SMN1; SMN2 | |
| SCHEMBL996002 | 0.65 | USP2 (0.46) | USP2SMN1; SMN2NR1H2 | |
| SCHEMBL1435794 | 0.64 | BUB1 (0.42) | CHRM2CHRM3CHRM1USP2SMN1; SMN2 | |
| SCHEMBL1401215 | 0.64 | BUB1 (0.37) | CHRM2CHRM3CHRM1USP2SMN1; SMN2 | |
| SCHEMBL18390155 | 0.64 | CYP11B2 (0.51) | USP2SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | claimed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
| US-7049321-B2 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2006-05-23 | — | — | US | disclosed |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | CHRM2 365/4885CHRM3 302/4885CHRM1 1260/4885 |
| US-20040044018-A1 | Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor | PMP22, PYGB, GAP43 | CHRM2 543/4885CHRM3 431/4885CHRM1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.